We scan new podcasts and send you the top 5 insights daily.
Tina says her West Virginia site is ninety minutes from academic care, and older follicular lymphoma patients often decline bispecifics because of travel and parking. Spencer sees the same barrier at his Boca Raton site. Repeated bispecific visits are harder than a one-time CAR T trip.
The systemic process for referring SCLC patients from community clinics to academic centers for trials is too slow. The most effective solution is not a systems overhaul but for community physicians to build direct communication channels (text, email) with academic specialists to "make a spot" and bypass formal referral backlogs.
Advanced SCLC therapies like the bispecific antibody tarlatumab require inpatient administration for the first two doses to manage severe side effects like Cytokine Release Syndrome (CRS). Many community centers lack the specialized cellular therapeutics or transplant teams necessary for this complex monitoring, creating an implementation gap.
The cumulative time spent coordinating care, attending appointments, and managing side effects is a significant resource drain termed "time toxicity." It disproportionately harms patients with inflexible jobs, caregiving duties, or limited travel funds, directly worsening health disparities in cancer treatment.
The 'brain to vein time'—from identifying a relapse to CAR T infusion—is critical. Early referral allows the specialty center to manage complex logistics like insurance authorization, organ function optimization, and patient travel, which can be significant barriers to care. Delays can mean a patient's condition deteriorates past the point of eligibility.
In clinical practice, the choice between competing post-neoadjuvant antibody-drug conjugate (ADC) trials is often driven by the practical reality of which study is open and geographically accessible, rather than a clear biological signal suggesting one ADC is superior.
Bispecific antibodies are "off-the-shelf" therapies with manageable side effects that don't require specialized manufacturing centers like CAR T. This allows community practices to administer highly effective T-cell redirecting therapies, equalizing access for patients far from major academic institutions.
Despite its approval, the bispecific T-cell engager tarlatamab sees slower community adoption than prior SCLC drugs. The barrier is the logistical need for inpatient monitoring and specialized supportive care for potential cytokine release syndrome during the first two doses, a new challenge for community practices that suggests a university collaboration model.
Spencer, at Lynn Cancer Institute, says his committee had to update multiple EMRs, teach ER doctors, ICU staff, residents and hospitalists about CRS, ensure tocilizumab is available after hours, and secure STAT CMP testing. He describes the coordination across stakeholders as very difficult and the main operational barrier to launching bispecifics.
With several viable treatment options available, practical considerations are becoming as important as clinical data. A patient's ability to travel, manage weekly infusions, or handle side effects of oral medication are now critical factors in shared decision-making for personalized treatment plans.
True scaling of complex treatments goes beyond logistics. It requires building flexibility into the system to accommodate patients' variable health, reducing the emotional and financial burden of travel for them and their families.